Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
about
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluidProperties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylateExtensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg dailySunitinib and other targeted therapies for renal cell carcinoma.E- and p-selectins are essential for repopulation of chronic myelogenous and chronic eosinophilic leukemias in a scid mouse xenograft modelChronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinAllogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.Therapy of chronic myeloid leukemia: twilight of the imatinib era?State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment.Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.Why doesn't imatinib cure chronic myeloid leukemia?Insights into the stem cells of chronic myeloid leukemia.Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications.Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment.Dasatinib Induced Cardiac Tamponade-A Rare Association.Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib.Long-term treatment effects in chronic myeloid leukemia.Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment.Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
P2860
Q28081844-0E1D5F9A-464A-4ACD-A690-6E0CAF6C99D7Q33841347-B4965E5F-E113-42D3-8BD0-C4FBD7849C30Q34184723-F318557E-8AE7-4E11-A3E7-C6FD7E794357Q34451624-341CE6AE-6068-4071-8077-D4CB4A9E6185Q34621802-2BDB0595-72A4-4266-854F-54C6C9EF56F9Q34906157-E4D055F6-289D-4136-8213-F2C6489C9B25Q35640320-8B37D918-B4A0-411D-8166-081D1764983BQ35717808-CC66349A-41A9-4455-BC6E-49FE509D6A5DQ36741655-1AEA5E07-22A9-4A65-AC66-A76D123F1648Q36755221-23E90A1E-A8E8-468B-A466-05A87A39F926Q37593435-49460ACE-E6FE-469B-9024-35DDEFF4B288Q37657478-16ADB0E1-8A57-4D12-9B84-AD32FF1F8E7DQ37663655-E36CA5A7-9B6A-4C4A-9B82-51D9A488A560Q37685843-5FD8CF07-BC21-4F30-99C0-071E8771B071Q37791423-14FA76FB-AF19-481A-8851-734E5A5B4CBDQ38193659-23E30C93-AB16-4E5F-8818-A12A3B8CABBEQ38265115-09303E0C-9316-4A0E-BBE8-F3C813022ACEQ38812117-FEB786B7-D8AE-459B-8BD8-2407253D411CQ39742346-13139415-E693-443B-9A68-1161E7C6FDF4Q42293055-723691BC-B0B8-4B6D-8D8D-70542BFC887CQ47117016-A9799D18-D6BB-4A8C-A515-1E8238F13578Q47136924-ADA9C317-819E-455E-8FD6-9F3EAB0BEBB5Q47995574-4EAA82EA-C2CB-4058-BA09-9D5E36258D27Q50123249-530CB94E-C170-4997-9866-671403807EF2Q51373837-066A37BE-6AA6-4DAE-AA81-8F56759CA060
P2860
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging stem cell concepts fo ...... t, and therapy of the disease.
@en
Emerging stem cell concepts fo ...... t, and therapy of the disease.
@nl
type
label
Emerging stem cell concepts fo ...... t, and therapy of the disease.
@en
Emerging stem cell concepts fo ...... t, and therapy of the disease.
@nl
prefLabel
Emerging stem cell concepts fo ...... t, and therapy of the disease.
@en
Emerging stem cell concepts fo ...... t, and therapy of the disease.
@nl
P2860
P1476
Emerging stem cell concepts fo ...... nt, and therapy of the disease
@en
P2093
Peter Valent
P2860
P304
P356
10.1111/J.1365-2141.2008.07197.X
P407
P50
P577
2008-06-05T00:00:00Z